Sentinel Lymph Node Biopsy in Cutaneous Melanoma: Results of a Single-Center Analysis

Sentinel lymph node biopsy (SLNB) in cutaneous melanoma is a staging step in cases of unaffected regional lymph nodes. This method is included in routine practice in many medical facilities of the Russian Federation.

Aim. To analyze the results of SLNB in cutaneous melanoma performed using gamma scintigraphy technique with the 99mTc-containing technefit radiopharmaceutical agent.

Materials and methods. The prospective study included 97 patients (39.2 % (38/97) men and 60.8 % (59/97) women) with primary cutaneous melanoma who received surgical treatment at the Republican Clinical Oncological Dispensary (Ufa) between February of 2021 and January of 2023. Mean patient age was 57.2 ± 13.2 years (95 % confidence interval (CI) 53.8–61.3 years), mean Breslow thickness per biopsy and histological examination after wide tumor resection was 2.89 ± 2.7 mm (95 % CI 2.2–3.76 mm), median follow-up period was 14 months (interquartile range 8–18 months). 99mTc-containing technefit radiopharmaceutical agent was administered intradermally around melanoma/scar. Accumulation of the radiopharmaceutical in the regional lymph nodes was evaluated using single-photon emission computed tomography/computed tomography (SPECT/CT). Intraoperatively the sentinel lymph node (SLN) was identified using a portable gamma probe. Morphological evaluation was performed in accordance with the protocol approved at the Republican Clinical Oncological Dispensary and based on the updated protocol of the European Organisation for Research and Treatment of Cancer (EORTС) (2019).

Results. The percentage of successfully mapped SLNs after radiopharmaceutical administration was 93.8 % (91/97). Mean number of visualized SLNs per SPECT/CT data was 1.7 ± 1.1 SLN (95 % CI 1.5–1.9). SLN biopsy was performed in 91.8 % (89/97) patients. Mean number of identified SLNs during SLNB was 1.9 ± 1.2 (95 % CI 1.6–2.3). Histological and immunohistochemical examinations showed SLN metastases in 22.5 % (20/89) patients; in 77.5 % (69/89) patients, no lymph node metastases were found. SLN biopsy allowed to perform disease staging. During follow-up in 3 patients with negative SLNs metastases in the regional lymph nodes were found, as well as in 2 patients with positive SLNs. The frequency of false negative SLNB results was 13 % (3/23), negative post-test probability was 2.8 % (2/69). V600E mutation in the BRAF gene was found in 42.3 % (22/52) patients.

Conclusion. SLN biopsy using the technefit radiopharmaceutical showed satisfactory results: SLNs were identified in 93.8 % of cases. Morphological examination showed SLN metastases in 22.5 % (20/89) of patients.

1. Morton D.L., Thompson J.F., Cochran A.J. et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355(13):1307–17. DOI: 10.1056/NEJMoa060992

2. Faries M.B. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376(23):2211–22. DOI: 10.1056/NEJMoa1613210

3. Musin Sh.I., Zamilov M.M., Menshikov K.V. et al. The experience of biopsy of signaling lymph nodes in skin melanoma in the Republic of Bashkortostan. Voprosy onkologii = Oncology Issues 2023;69(3S-1): 109–10. (In Russ.).

4. Gress D.M., Edge S.B., Gershenwald J.E. et al. Principles of cancer staging. In: AJCC Cancer Staging Manual. Ed. by M.B. Amin, S.B. Edge, F.L. Greene et al. 8th edn. New York: Springer, 2017. Pp. 3–30.

5. The TNM classification of malignant tumours. 8th edn. Ed. by J.D. Brierley, M.K. Gospodarowicz, C. Wittekind. Oxford: Wiley Blackwell, 2017.

6. Gershenwald J.E., Scolyer R.A., Hess K.R. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(6): 472–92. DOI: 10.3322/caac.21409

7. Morton D.L, Cochran A.J., Thompson J.F. et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242(3):302–11; discussion 311–3. DOI: 10.1097/01.sla.0000181092.50141.fa

8. Leiter U., Stadler R., Mauch C. et al. German Dermatologic Cooperative Oncology Group (DeCOG). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17(6):757–67. DOI: 10.1016/S1470-2045(16)00141-8

9. Dummer R., Hauschild A., Santinami M. et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383(12):1139–48. DOI: 10.1056/NEJMoa2005493

10. Eggermont A.M.M., Blank C.U., Mandalà M. et al. EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22(5):643–54. DOI: 10.1016/S1470-2045(21)00065-6

11. Ascierto P.A., Del Vecchio M., Mandalá M. et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21(11):1465–77. DOI: 10.1016/S1470-2045(20)30494-0

12. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.

13. Michielin O., van Akkooi A., Lorigan P. et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol 2020;31(11):1449–61. DOI: 10.1016/j.annonc.2020.07.005

14. Aliyev M.D., Bulanov A.A., Butenko A.V. et al. Melanoma of the skin and mucous membranes: clinical recommendations. Moscow: LLC “Practical medicine”, 2020. 144 p. (In Russ.).

15. Valsecchi M.E., Silbermins D., de Rosa N. et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a metaanalysis. J Clin Oncol 2011;29(11):1479–87. DOI: 10.1200/JCO.2010.33.1884

16. de Rosa N., Lyman G.H., Silbermins D. et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011;145(3):375–82. DOI: 10.1177/0194599811408554

17. Al Ghazal P., Gutzmer R., Satzger I. et al. Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas. Melanoma Res 2014;24(2):158–64. DOI: 10.1097/CMR.0000000000000042

18. Poluektova Yu.V., Kharatishvili T.K., Vishnevskaya Ya.V. Biopsy of the sentinel lymph node in primary melanoma of the skin. Vestnik RONTC im. N.N. Blohina RAMN = Bulletin of the N.N. Blokhin Russian Research Center of the Russian Academy of Sciences 2011;22(3):4–11. (In Russ.).

19. Testori A., De Salvo G.L., Montesco M.C. et al. Italian Melanoma Intergroup. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol 2009;16(7):2018–27. DOI: 10.1245/s10434-008-0273-8

20. Ebert M.A., Zinoviev G.V., Gafton I.G. et al. BSLU for skin melanoma: the experience of the N.N. Petrov NMIC of Oncology. Voprosy onkologii = Oncology Issues 2023;69(3S1):106–7. (In Russ.).

21. Kudryavtsev D.V., Kudryavtseva G.T., Gumenetskaya Yu.V. et al. Shortterm and long-term results of sentinel lymph node biopsy in patients with localized cutaneous melanoma. Sarkomy kostei, miagkikh tkanei i opukholi kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin 2019;11(3):16–27. (In Russ.).